OBJECTIVES: To determine the prevalence of cervical Pap screening (CPAP-S), identify factors associated with CPAP-S, and explore risk factors for abnormal cervical cytology in female adolescents with perinatally and behaviorally acquired HIV infection. DESIGN: Cross-sectional. SETTING: LEGACY is a national observational cohort chart review study of 1478 HIV-infected persons (<age 24 years) managed in 22 HIV specialty clinics in the United States. PARTICIPANTS: Sexually active females aged 13-24 years in the LEGACY cohort. MAIN OUTCOME MEASURES: CPAP-S and abnormal cervical cytology. RESULTS: Of 231 sexually active female LEGACY participants 13-24 years of age 49% had documentation of CPAP-S between 2001 and 2006. Fifty-eight percent of 113 cervical tests were abnormal (2% high-grade). In multivariable analysis, perinatal HIV infection and black race were associated with decreased likelihood of CPAP-S (adjusted prevalence ratio [APR] 0.66, 95% CI 0.45-0.96 and APR 0.74, 95% CI 0.56-0.96, respectively). Presence of any sexually transmitted infection (STI) was independently associated with increased likelihood of CPAP-S (APR 1.56, 95% CI 1.21, 2.02). CD4+ T-lymphocyte count <200 cells/mL and previous STI diagnosis were independently associated with increased likelihood of abnormal cervical cytology (APR 2.19, 95% CI 1.26-3.78 and APR 1.94, 95% CI 1.29-2.92, respectively). CONCLUSIONS: Among sexually active HIV-infected adolescent females, prevalence of CPAP-S was low and cytology was abnormal in more than half of Pap smears. Perinatally HIV-infected, sexually active females were less likely to undergo CPAP-S than their behaviorally HIV-infected counterparts. Interventions targeted at HIV-infected adolescents and care providers are needed to improve CPAP-S in HIV-infected young women, especially those with perinatally acquired HIV infection.
OBJECTIVES: To determine the prevalence of cervical Pap screening (CPAP-S), identify factors associated with CPAP-S, and explore risk factors for abnormal cervical cytology in female adolescents with perinatally and behaviorally acquired HIV infection. DESIGN: Cross-sectional. SETTING: LEGACY is a national observational cohort chart review study of 1478 HIV-infectedpersons (<age 24 years) managed in 22 HIV specialty clinics in the United States. PARTICIPANTS: Sexually active females aged 13-24 years in the LEGACY cohort. MAIN OUTCOME MEASURES: CPAP-S and abnormal cervical cytology. RESULTS: Of 231 sexually active female LEGACY participants 13-24 years of age 49% had documentation of CPAP-S between 2001 and 2006. Fifty-eight percent of 113 cervical tests were abnormal (2% high-grade). In multivariable analysis, perinatal HIV infection and black race were associated with decreased likelihood of CPAP-S (adjusted prevalence ratio [APR] 0.66, 95% CI 0.45-0.96 and APR 0.74, 95% CI 0.56-0.96, respectively). Presence of any sexually transmitted infection (STI) was independently associated with increased likelihood of CPAP-S (APR 1.56, 95% CI 1.21, 2.02). CD4+ T-lymphocyte count <200 cells/mL and previous STI diagnosis were independently associated with increased likelihood of abnormal cervical cytology (APR 2.19, 95% CI 1.26-3.78 and APR 1.94, 95% CI 1.29-2.92, respectively). CONCLUSIONS: Among sexually active HIV-infected adolescent females, prevalence of CPAP-S was low and cytology was abnormal in more than half of Pap smears. Perinatally HIV-infected, sexually active females were less likely to undergo CPAP-S than their behaviorally HIV-infected counterparts. Interventions targeted at HIV-infected adolescents and care providers are needed to improve CPAP-S in HIV-infected young women, especially those with perinatally acquired HIV infection.
Authors: J M Palefsky; H Minkoff; L A Kalish; A Levine; H S Sacks; P Garcia; M Young; S Melnick; P Miotti; R Burk Journal: J Natl Cancer Inst Date: 1999-02-03 Impact factor: 13.506
Authors: Anna-Barbara Moscicki; Stephen Shiboski; Nancy K Hills; Kimberly J Powell; Naomi Jay; Evelyn N Hanson; Susanna Miller; K Lisa Canjura-Clayton; Sepidah Farhat; Jeanette M Broering; Teresa M Darragh Journal: Lancet Date: 2004 Nov 6-12 Impact factor: 79.321
Authors: G Rezza; M Giuliani; M Branca; A Benedetto; G Migliore; A R Garbuglia; C D'Ubaldo; P Pezzotti; G Cappiello; D Pomponi Formiconi; B Suligoi; A Schiesari; G Ippolito; G Giacomini Journal: Eur J Epidemiol Date: 1997-12 Impact factor: 8.082
Authors: L S Massad; K A Riester; K M Anastos; R G Fruchter; J M Palefsky; R D Burk; D Burns; R M Greenblatt; L I Muderspach; P Miotti Journal: J Acquir Immune Defic Syndr Date: 1999-05-01 Impact factor: 3.731
Authors: C Six; I Heard; C Bergeron; G Orth; J D Poveda; P Zagury; P Cesbron; C Crenn-Hébert; R Pradinaud; M Sobesky; C Marty; M L Babut; J E Malkin; A Odier; S Fridmann; J P Aubert; J B Brunet; I de Vincenzi Journal: AIDS Date: 1998-06-18 Impact factor: 4.177
Authors: Milena Camargo; Sara C Soto-De Leon; Marina Munoz; Ricardo Sanchez; Diego Peña-Herrera; Andrea Clemencia Pineda-Peña; Otto Sussmann; Carol Paez; Antonio Perez-Prados; Manuel Elkin Patarroyo; Manuel Alfonso Patarroyo Journal: BMC Cancer Date: 2014-06-18 Impact factor: 4.430